Bristol-Myers Squibb Selling Global Diabetes Business

Bristol-Myers Squibb Selling Global Diabetes Business 

Bristol-Myers Squibb is selling its global diabetes business which includes the blockbuster drugs Byetta, Bydureon, and Onglyza, to AstraZeneca.